Skip to content
Head to head

Royalty Pharma vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: RPRX · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

RPRX +77.8%VRTX +18.7%
It’s close.
RPRXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price68.45515.02
Change today+1.08%-1.08%
1-year return+81.4%+22.0%
Market cap$30.48B$130.58B
52-week range36.68 – 70.13412.27 – 568.67
Valuation
P/E (TTM)44.7433.14
P/E percentile, own 5-yr range84th99th
P/B4.466.25
Dividend yield1.35%0.00%
Profitability & growth
EPS (TTM)1.7815.32
Net profit (TTM)$792.57M$3.88B
Revenue (TTM)$2.62B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+13.3%+11.8%
Gross margin--85.5%
Operating margin65.5%33.1%
Net margin25.7%30.7%
Free cash flow (TTM)$2.96B$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership87.6%96.8%
Insider activity (12mo)25 buy / 25 sell28 buy / 22 sell
Short interest (% of float)2.9%1.9%
Analyst consensus100% buy (6)95% buy / 5% hold (21)
Analyst price target$73 (+6%)$624 (+21%)
StockVane view
StockVane Quant RatingC (95)C (68)
Company
Employees1006,400
Founded20201989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.